Friday, 24 April 2026 — Publication BB Biotech Interim Report Q1 2026 To the report

Friday, 24 April 2026 — Publication BB Biotech Interim Report Q1 2026 To the report

Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its interim report

24.04.2026

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2026, which covers the results of its business activities for the first three months of 2026.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2026, amounted to CHF 21 mn (loss of CHF 241 mn in the same period 2025). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2026, is available under www.bbbiotech.com.

 

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

Head BB Biotech Team
Dr. Christian Koch

Head Investor Relations
ir@bbbiotech.com
Rachael Burri, rbu@bellevue.ch

Media Relations
Tanja Chicherio, tch@bellevue.ch